Two decades of orphan product development

被引：101

作者：

Haffner, ME ^{[1
]}

Whitley, J ^{[1
]}

Moses, M ^{[1
]}

机构：

[1] US FDA, Off Orphan Prod Dev, Rockville, MD 20857 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2002年 / 1卷 / 10期

关键词：

D O I：

10.1038/nrd919

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Over the past 20 years, incentives of the Orphan Drug Act (ODA), the largest single source of extramural clinical grants at the US Food and Drug Administration, have had a substantial impact on public health. ODA incentives have contributed to the development of many innovative biotechnology products, and as our understanding of the human genome evolves, it is anticipated that pharmacogenomics will result in the identification of more 'orphan diseases'.

引用

页码：821 / 825

页数：5